Discoveries in Breast Cancer Treatment Practices at Atossa

Innovative Discoveries in Breast Cancer Treatment

SEATTLE — Atossa Therapeutics, Inc. (NASDAQ: ATOS), a pioneering clinical stage biopharmaceutical company, has made significant strides in the field of oncology, specifically in breast cancer treatments. The company has successfully leveraged advanced discovery methods to identify new compounds that may work synergistically with (Z)-endoxifen, a powerful Selective Estrogen Receptor Modulator (SERM). The results of these promising findings will be shared at the prestigious San Antonio Breast Cancer Symposium.

Exploiting Synergistic Potentials

Atossa’s recent research focuses on compounds that show potential to enhance the efficacy of (Z)-endoxifen, the most potent SERM available today. The poster presentation at the symposium will detail their innovative approaches utilizing insilico analysis and comprehensive chemical screening techniques. These methods led to the identification of compounds that inhibit crucial enzymes responsible for cancer cell growth and survival, including DNA topoisomerase and mTOR, as well as various protein kinases like CDK and AKT.

Combination Therapies Advancing Cancer Treatment

The findings demonstrate that when paired with (Z)-endoxifen, these newly discovered agents have been shown to induce greater cell death in MCF-7 breast cancer cells—much more than either agent could achieve alone. This synergistic effect underscores the importance of combination therapies in fighting breast cancer effectively. Notably, various MEK, PI3K, and AKT inhibitors exhibited significant potential in reducing cell viability, suggesting that their future combination with (Z)-endoxifen may lead to even more effective treatment strategies.

Leadership Insight

Steven Quay, M.D., Ph.D., the President and CEO of Atossa Therapeutics, emphasized the significance of these discoveries, stating, “Our research team's accomplishments highlight our ongoing mission to reshape the norms in breast cancer treatment. These findings could potentially transform therapeutic strategies and offer new hope to patients.”

Poster Presentation Details

The poster titled “Discovery of molecules synergistic with (Z)-endoxifen for the treatment of breast cancer” will be presented by researcher Daniela Hühn, scheduled for December 13. The key aspects of this presentation will include a comprehensive analysis of the findings regarding synergistic compounds and their applications in advanced therapeutic methods.

A Closer Look at (Z)-Endoxifen

(Z)-endoxifen, which acts not only to inhibit estrogen receptors but also promotes their degradation, has shown promise especially in patients who do not respond to conventional hormonal treatments. This compound operates effectively at clinically relevant concentrations targeting oncogenic proteins, thus presenting itself as a formidable agent in the fight against breast cancer while limiting adverse effects typically associated with other treatments.

Ongoing Development of (Z)-Endoxifen

Atossa Therapeutics is developing a proprietary formulation of (Z)-endoxifen designed to eliminate the need for liver metabolism to achieve therapeutic levels. This formulation is encapsulated to bypass the stomach, preventing premature conversion to the inactive (E)-endoxifen. Positive results have already emerged from Phase 1 and small Phase 2 trials, paving the way for further studies that continue exploring its efficacy in preventing and treating breast cancer.

About Atossa Therapeutics

Atossa Therapeutics, focusing on breast cancer, is dedicated to translating unique scientific insights into groundbreaking therapies that address significant unmet medical needs. The company's commitment is reflected in its ongoing research to optimize the use of (Z)-endoxifen, aiming to offer improved treatment options for patients affected by this challenging disease.

Frequently Asked Questions

What new findings did Atossa Therapeutics announce?

Atossa announced the discovery of compounds that may work synergistically with (Z)-endoxifen, enhancing breast cancer treatment effectiveness.

What is (Z)-endoxifen?

(Z)-endoxifen is a potent SERM used to inhibit estrogen receptors and has been shown effective against hormone-resistant cancers.

What methods were used to discover the new compounds?

The company employed insilico and chemical screening approaches to identify molecules that could complement (Z)-endoxifen.

When will the findings be presented?

The research findings will be presented at the San Antonio Breast Cancer Symposium on December 13.

Is Atossa’s (Z)-endoxifen well tolerated?

Yes, initial Phase 1 and Phase 2 studies indicate that Atossa’s formulation of (Z)-endoxifen is well tolerated among participants.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.